A Structural View at Vaccine Development against M. tuberculosis.

Area of Science:

• * Infectious disease epidemiology and vaccinology.
• * Application of structural biology and immunology in vaccine development.

Background:

• * Tuberculosis (TB) remains a leading cause of death from infectious bacterial agents globally.
• * The existing Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine, used since 1921, offers insufficient protection, necessitating novel vaccine strategies.
• * Despite decades without new vaccines, TB research has accelerated due to technological advancements and rational vaccine design.

Purpose of the Study:

• * To review recent progress in TB vaccine development across various clinical phases.
• * To highlight the role of Structural Vaccinology (SV) in creating safer and more effective TB vaccine antigens.
• * To emphasize the potential of subunit vaccines, enhanced by SV and adjuvants, for improved TB control.

Main Methods:

• * Comprehensive literature review of current TB vaccine research and clinical trials.
• * Analysis of the contribution of Structural Vaccinology (SV) to antigen design and understanding immune responses.
• * Evaluation of strategies for re-engineering subunit vaccines to enhance immunogenicity.

Main Results:

• * Structural Vaccinology (SV) facilitates the development of safer subunit vaccines by providing detailed antigen structural information.
• * SV, combined with adjuvant development, addresses the challenge of low immunogenicity in subunit vaccines.
• * Advances in understanding host immune responses to TB infection are crucial for rational vaccine design.

Conclusions:

• * Novel TB vaccines are urgently needed, with subunit vaccines offering a promising, safer alternative to BCG.
• * Structural Vaccinology (SV) is pivotal in re-engineering subunit vaccines for enhanced efficacy.
• * Continued research integrating SV, adjuvant technology, and immune response understanding will accelerate the development of effective TB vaccines.